Article
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2014
Borger Darrell R, Goyal Lipika, Yau Thomas, Poon Ronnie T, Ancukiewicz Marek, Deshpande Vikram, Christiani David C, Liebman Hannah M, Yang Hua, Kim Hyeryun, Yen Katharine, Faris Jason E, Iafrate A John, Kwak Eunice L, Clark Jeffrey W, Allen Jill N, Blaszkowsky Lawrence S, Murphy Janet E, Saha Supriya K, Hong Theodore S, Wo Jennifer Y, Ferrone Cristina R, Tanabe Kenneth K, Bardeesy Nabeel, Straley Kimberly S, Agresta Sam, Schenkein David P, Ellisen Leif W, Ryan David P, Zhu Andrew X
Abstract excerpt
PURPOSE: Mutations in the IDH1 and IDH2 (IDH1/2) genes occur in approximately 20% of intrahepatic cholangiocarcinoma and lead to accumulation of 2-hydroxyglutarate (2HG) in the tumor tissue. However, it remains unknown whether IDH1/2 mutations can lead to high levels of 2HG circulating in the blo...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.